Headquartered in Palo Alto, CA Fiscal year ends December NASDAQ: KOD kodiak.com
Kodiak Sciences is a precommercial, retina-focused biotechnology company. It develops intravitreal biologic medicines for leading causes of blindness on its proprietary ABC (Antibody Biopolymer Conjugate) platform, which is designed to extend ocular durability. It has three late-stage programs:
- Zenkuda (tarcocimab tedromer): an anti-VEGF biopolymer conjugate with a roughly 20-day ocular half-life. It has five successful Phase 3 studies in wet AMD, diabetic retinopathy and retinal vein occlusion, and a three-indication BLA is planned for Q4 2026.
- Tabirafusp-ted (KSI-501): an anti-IL-6/VEGF-trap bispecific. It met its Phase 3 DAYBREAK endpoints in wet AMD and is enrolling the Phase 3 ALTO study in diabetic macular edema.
- KSI-101: a high-strength (100 mg/mL) IL-6/VEGF bispecific for macular edema secondary to inflammation (MESI), an indication with no approved intravitreal biologic. It is in the Phase 3 PEAK and PINNACLE studies.
Zenkuda and KSI-501 target the roughly $15 billion anti-VEGF retinal vascular disease market, while MESI represents a separate market segment. The company has no product revenue and funds operations largely through equity raises, including an at-the-market facility. Updated
A $6.8 billion market cap now rests on $88.7 million of cash and a going-concern warning, even after a $69 million post-quarter stock sale. The loss came in slightly wider than expected on R&D of $58.3 million, but the real catalyst is December: the first Phase 3 KSI-101 readout, with the three-indication Zenkuda filing due by year-end.
Kodiak Sciences tripled in a single session after its eye drug cleared a pivotal trial, but a cash-burning biotech with no revenue and a likely share offering complicates any case for chasing…
Kodiak Sciences, Medline, and W.R. Berkley have seen some huge insider purchases, and there were some other notable insider purchases as well..
Tuesday's additional top analyst upgrades and downgrades included Cracker Barrel, Farfetch, Intel, Kodiak Sciences, Pinterest, Snowflake, Teladoc and more.
Friday's top analyst upgrades and downgrades included Dish Network, Dollar General, eBay, Gap, HollyFrontier, Mosaic, NetApp, Nextdoor, Skillz, Tesla, TJX, Toll Brothers and Vipshop.
Thursday afternoon's top analyst upgrades and downgrades included FuboTV, Grab, Infosys, Intel, Macy’s, Mattel and Under Armour.
Wednesday afternoon's top analyst upgrades and downgrades included Advanced Micro Devices, Clorox, Clover Health Investments, Datadog, Electronic Arts, Etsy, General Motors, Intuitive Surgical, Starbucks and Under Armour.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Friday, including Nielsen, Nordstrom, PayPal, StoneCo and more.
Kodiak Sciences is a precommercial, retina-focused biotechnology company. It develops intravitreal biologic medicines for leading causes of blindness on its proprietary ABC (Antibody Biopolymer Conjugate) platform, which is designed to extend ocular durability.
The Wall Street consensus 12-month price target for KOD is $121.67.
